Product
Recombinant humanized IL-17A Monoclonal Antibody
1 clinical trial
1 indication
Indication
Ankylosing spondylitisClinical trial
A Phase II, Randomized, Double-blind, Placebo-controlled , Multicenter Study to Evaluate the Preliminary Efficacy and Safety of Subcutaneous Injection of Recombinant Humanized Anti-IL-17A Monoclonal Antibody（JS005） in Adult Patients With Active Ankylosing SpondylitisStatus: Recruiting, Estimated PCD: 2025-02-26